Last reviewed · How we verify
Somatostatin analog
Somatostatin analogs bind to somatostatin receptors on neuroendocrine tumor cells and other tissues, inhibiting hormone secretion and slowing tumor growth.
Somatostatin analogs bind to somatostatin receptors on neuroendocrine tumor cells and other tissues, inhibiting hormone secretion and slowing tumor growth. Used for Neuroendocrine tumors (gastroenteropancreatic and thoracic), Acromegaly, Variceal bleeding in portal hypertension.
At a glance
| Generic name | Somatostatin analog |
|---|---|
| Also known as | lanreotide, octreotide, sandostatin, somatuline, Arm A |
| Sponsor | The Netherlands Cancer Institute |
| Drug class | Somatostatin receptor agonist |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Somatostatin analogs are synthetic derivatives of the natural hormone somatostatin that activate somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells. This activation suppresses the release of various hormones and growth factors, reducing symptoms from hormone excess and slowing proliferation of somatostatin receptor-positive tumors. They are commonly used in neuroendocrine tumors and gastroenteropancreatic neuroendocrine neoplasms.
Approved indications
- Neuroendocrine tumors (gastroenteropancreatic and thoracic)
- Acromegaly
- Variceal bleeding in portal hypertension
- Carcinoid syndrome
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Cholelithiasis
- Hyperglycemia
- Injection site reactions
Key clinical trials
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs (PHASE3)
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (PHASE3)
- RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
- Prevention of Postoperative Pancreatic Fistula by Somatostatin (PHASE3)
- Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics (PHASE2, PHASE3)
- Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Somatostatin analog CI brief — competitive landscape report
- Somatostatin analog updates RSS · CI watch RSS
- The Netherlands Cancer Institute portfolio CI